Recent Updates
Recently added Catalysts

BioVie Inc.

BIVIFDA catalysts, PDUFA dates & pipeline intelligence
$1.33
▲ +0.12 · +9.92%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full BIVI financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.8252W HIGH $3.79
Volume
181.81 K
Value Traded
240.39 K
Short % Float
6.62%
Days to Cover
2.8
-6.99%Week
-5%1 Month
+33.09%3 Month
-9.52%6 Month
-99.89%5 Year
-99.98%All Time

Cash Data

Unlock BIVI cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
11.55 M
EPS (TTM)
-2.54
P/E Ratio
-
Ent. Value
2.57 M
Total Shares
8.68 M
Float Shares
8.22 M
Insiders
3.63%
Institutions
25.58%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data presentation
bezisterim (NE3107)
Long COVID
Phase 2Small MoleculesNervous System
Unlock every BIVI catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

BIVI Catalyst Timeline

Dated clinical, regulatory and corporate events for BioVie Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for BioVie Inc.

333Total events
10Upcoming
70Tier-1 (high impact)
2018 to 2026Coverage

Upcoming catalysts 2

T2End Of Phase 2 Meeting
Subscribe to view catalyst details
NE3107
T1Late-Breaker
Subscribe to view catalyst details
NE3107

Event history 50

◆Timing GuidancePresentation
Expected closing of the offering
▼Equity OfferingCorporate
Pricing of $4.74 million registered direct offering and concurrent private placement
▲Full ResultsNE3107Clinical Data
Full SUNRISE-PD results presented, including significant motor and non-motor improvements in high-inflammation subgroup
Parkinson's diseasesource ↗
●AbstractNE3107Presentation
SUNRISE-PD abstract published in Annals of Neurology (Vol. 100, pp. S4-S375)
Parkinson's diseasesource ↗
▲Topline ReadoutNE3107Clinical Data
ADDRESS-LC Phase 2 results: consistent trend in ITT, statistically significant improvements in high-baseline-burden subgroups
Long COVIDsource ↗
▲Safety Data UpdateNE3107Clinical Data
ADDRESS-LC safety: TEAEs 41.6% bezisterim vs 55.9% placebo; no serious TEAEs in bezisterim group
Long COVIDsource ↗
●Poster PresentationNE3107Presentation
Poster presentation of ADDRESS-LC results in Long COVID at 2026 ANA Annual Meeting
Long COVIDsource ↗
●Poster PresentationNE3107Presentation
Poster presentation of ADDRESS-LC Phase 2 results in Long COVID at ANA2026
Long COVIDsource ↗
▲Poster PresentationNE3107Presentation
Poster presentation of SUNRISE-PD results in early Parkinson's disease at ANA 2026
Parkinson's diseasesource ↗
●AbstractNE3107Presentation
Two bezisterim abstracts accepted for presentation at ANA2026
Long COVID; Parkinson's diseasesource ↗
Unlock the full BIVI catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How BIVI actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-05bezisterim (NE3107) Phase 2 data presentation Phase 2
Unlock 9 more BIVI historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 75%
Micro Cap
(rank 505 of 673)
Percentile Rank
Showing 3 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
NE3107 Small MoleculesCompletedNCT06847191Long COVIDPhase 2 COMPLETED 203Sep 2, 2026
NE3107 Small MoleculesCompletedNCT05083260Parkinson DiseasePhase 2 COMPLETED 103Jan 4, 2023
Terlipressin continuous infusion Small MoleculesCompletedNCT03107091CirrhosisPhase 2 COMPLETED 6Apr 25, 2019
Unlock the BIVI pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every BIVI program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
bezisterim Long COVIDPhase 22026-11-0278% of trial participants in at least one domain experienced symptoms affecting; consistent trend toward improvement across most patient-reported and objective efficacy measures compared with placeboRead MoreBioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026Read More
Scroll for more · summaries link to the source press release
Unlock every BIVI trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock BIVI insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Palumbo Joseph MOfficer (Chief Medical Officer)Buy 4,843 6,036 held$2.16 08/28/2026
Unlock the full BIVI insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Ikarian Capital, LLC 0.2 % (-33.3 %) 1.56 M 457.35 K 1.96% ( 8.79 K)
Unlock every fund holding BIVI
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in BIVI
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see BIVI ownership
Insider and institutional ownership, quarter by quarter.

BIVI Short Interest

Shares sold short, counted twice a month.

6.62%
Short % of Float
of tradable shares sold short
544.4K
Shares Sold Short
-34.5% vs prior count
2.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
196.9K
Avg Daily Volume
the average used for days to cover
Unlock BIVI short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock BIVI option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live BIVI option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock BIVI options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How BIVI ranks across every disease it competes in

Competitive Position is a premium feature
See how BIVI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

BIVI News

BIVI
Nov 4, 2026
BIVIGeneral
▼ -22.5%on this news

BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

BioVie Inc. announced a registered direct offering and concurrent private placement, raising approximately $4.74 million. The offering involves 2,962,500 shares priced at $1.60 each and includes unregistered common warrants. The funds will be used for working capital and corporate purposes, with the closing expected on November 5, 2026.

Read more →
BIVI
Nov 2, 2026
BIVIConferences/Events

BioVie Selected for Late-Breaking Oral Presentation of Bezisterim Long COVID Data at the 4th Long COVID International Conference 2026

BioVie Inc. will present late-breaking data on bezisterim at the 4th Long COVID International Conference 2026. The ADDRESS-LC trial showed significant improvements in fatigue and cognition for patients with high symptom burdens. Dr. Penelope Markham will share new biomarker results alongside clinical findings during the session in Nice, France.

Read more →
BIVI
Oct 26, 2026
BIVIConferences/Events
▲ +7.3%on this news

BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop

BioVie Inc. has been invited to present data on bezisterim at the NIH's RECOVER-TLC workshop. Dr. Penelope Markham will discuss findings from the Phase 2 ADDRESS-LC trial, which indicated that bezisterim may improve neurological symptoms in Long COVID patients. The trial showed consistent trends toward improvement in various efficacy measures.

Read more →
BIVI
Oct 20, 2026
BIVIPhases
▼ -9.5%on this news

BioVie Presents Data on Bezisterim in Parkinson’s Disease at the 2026 American Neurological Association Annual Meeting

BioVie Inc. presented positive results from the Phase 2 SUNRISE-PD trial of bezisterim for early Parkinson's disease at the American Neurological Association meeting. The study demonstrated significant improvements in motor and non-motor symptoms, particularly in patients with elevated baseline inflammation. Bezisterim was well tolerated, with a favorable safety profile compared to placebo, supporting its potential as a treatment for Parkinson's disease.

Read more →
BIVI
Oct 19, 2026
BIVIPhases
▲ +14.2%on this newsshared move

BioVie Presents Data on Bezisterim in Long COVID at the 2026 American Neurological Association Annual Meeting

BioVie Inc. presented data from the Phase 2 ADDRESS-LC study on bezisterim for Long COVID at the 2026 American Neurological Association Annual Meeting. The study found that patients receiving bezisterim showed improvement in neurological symptoms, particularly those with severe baseline fatigue and cognitive impairment. The drug demonstrated a safety profile similar to placebo, with no serious adverse events reported. Further analysis of biomarkers is pending.

Read more →
BIVI
Oct 14, 2026
BIVIConferences/Events

BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting

BioVie Inc. announced that two abstracts from its Phase 2 trials of bezisterim for Long COVID and Parkinson's disease will be presented at the 2026 American Neurological Association Annual Meeting. The studies aim to evaluate the efficacy and safety of bezisterim, which targets neuroinflammation. While the results show promise, the ADDRESS-LC trial did not achieve overall statistical significance.

Read more →
BIVI
Sep 15, 2026
BIVIPhases
▼ -14.6%on this news

BioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie announced positive topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID. The trial demonstrated significant benefits in patients with high baseline symptom burden, with 21 out of 22 endpoints showing favorable trends. Bezisterim's safety profile was comparable to placebo, and the findings suggest potential for further development in a Phase 3 trial.

Read more →
BIVI
Sep 14, 2026
BIVIConferences/Events
▼ -14.6%on this newsshared move

BioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long Covid

BioVie Inc. will host a conference call on September 15, 2026, to discuss topline results from its Phase 2 ADDRESS-LC trial evaluating bezisterim for Long COVID. The trial aims to assess the drug's efficacy in reducing cognitive impairment and fatigue. Guest speakers include a trial investigator and a patient advocate, with a Q&A session to follow. The study is funded by a $13.13 million grant from the U.S. Department of War.

Read more →
BIVI
Sep 8, 2026
BIVIPhases

BioVie Announces Update to Parkinson’s Phase 3 Development Program

BioVie Inc. has announced the next steps in its Phase 3 development program for bezisterim, targeting Parkinson's disease. The trial will focus on both motor and non-motor symptoms, with MDS-UPDRS 1 Part III as the primary endpoint. Phase 2 data suggest significant benefits for patients with elevated inflammation. The company is seeking FDA feedback on the trial design.

Read more →
BIVI
Aug 31, 2026
BIVIPhases
▲ +5.6%on this news

BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Inc. has completed the treatment phase of its ADDRESS-LC Phase 2 trial, which evaluates bezisterim for neurological symptoms associated with Long COVID. The trial, funded by the U.S. Department of War, aims to assess the drug's efficacy in improving cognitive function and reducing fatigue. Topline results are expected by the end of September 2026.

Read more →
BIVI
Aug 6, 2026
BIVIPhases
▼ -33.8%on this news· ran to -51% by day 1

BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease

BioVie announced positive topline results from its Phase 2 SUNRISE-PD trial for bezisterim in early Parkinson's disease. The trial demonstrated significant improvements in both motor and non-motor symptoms compared to placebo, alongside beneficial effects on biomarkers of neurodegeneration and inflammation. The results suggest bezisterim may provide a new therapeutic approach targeting the underlying biology of Parkinson's disease.

Read more →
BIVI
May 27, 2026
BIVIConferences/Events

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

BioVie Inc. is hosting a live investor webinar on June 2, 2026, featuring CEO Cuong Do. The presentation will cover bezisterim, an investigational drug for neuroinflammation, and BIV201, a late-stage candidate for liver disease. The event will include a Q&A session, highlighting BioVie's progress and market opportunities.

Read more →
BIVI
May 26, 2026
BIVIPhases
▼ -5.3%on this newsshared move

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie Inc. has announced the full enrollment of its ADDRESS-LC Phase 2 trial, which evaluates bezisterim for treating neurological symptoms associated with Long COVID. The study is fully funded by a U.S. Department of War grant and aims to assess the drug's efficacy in alleviating cognitive impairment and fatigue. Topline data is expected to be released in late summer 2026.

Read more →
BIVI
May 18, 2026
BIVIPhases

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease

BioVie Inc. has completed the last patient evaluation visit for its Phase 2 SUNRISE-PD trial, which assesses the drug bezisterim in early-stage Parkinson's disease. The trial aimed to evaluate motor and non-motor endpoints and will now enter the closeout phase, with topline results anticipated in Q3 2026. The study utilized a hybrid decentralized design to enhance patient participation.

Read more →
BIVI
Apr 27, 2026
BIVIConferences/Events
▲ +6%on this newsshared move

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie Inc. is set to host a virtual KOL event on May 7, 2026, to discuss its Phase 2 study of bezisterim for Parkinson's disease. The event will feature Dr. Suzanne de la Monte, who will elaborate on bezisterim's mechanism of action. The drug has shown promise in improving motor control in patients with Parkinson's, with topline results expected in mid-2026.

Read more →
BIVI
Apr 14, 2026
BIVIConferences/Events
▲ +5.8%on this news

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie Inc. announced that an abstract from its SUNRISE-PD study on bezisterim has been accepted for presentation at the 2026 American Academy of Neurology Annual Meeting. The abstract will summarize initial data on patients with Parkinson's Disease and will be presented during a session focused on emerging therapeutics. Topline results from the study are anticipated in mid-2026.

Read more →
BIVI
Mar 12, 2026
BIVIConferences/Events

BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

BioVie Inc. announced that its abstract on bezisterim (NE3107) for Parkinson's disease has been accepted for presentation at the AD/PD 2026 conference in Copenhagen. The abstract summarizes initial data from the SUNRISE-PD study, which evaluates bezisterim's efficacy in early Parkinson's patients. Topline results are anticipated in mid-2026, highlighting the company's ongoing research in neurodegenerative diseases.

Read more →
BIVI
Feb 23, 2026
BIVIConferences/Events

Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4

BioVie Inc. is inviting investors to a webinar on March 4, 2026, featuring CEO Cuong Do. The session will cover the investigational drug bezisterim, which targets neuroinflammation and insulin resistance, and the orphan drug BIV201 for liver disease. The company is advancing multiple clinical programs with potential late-stage developments.

Read more →
BIVI
Feb 12, 2026
BIVIConferences/Events

BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting

BioVie Inc. announced the acceptance of two abstracts for its lead candidate, bezisterim, at the 2026 American College of Psychiatrists annual meeting. The abstracts focus on bezisterim's effects on Alzheimer's disease and Long COVID. The company has seen promising results in previous trials for Parkinson's disease and continues to explore bezisterim's therapeutic potential.

Read more →
BIVI
Jan 8, 2026
BIVIPhases

BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease

BioVie Inc. has successfully completed the enrollment of 60 participants in its Phase 2 SUNRISE-PD clinical trial, which is assessing the efficacy of bezisterim for early Parkinson's disease. This study focuses on individuals who have not previously received treatment with carbidopa/levodopa, utilizing a hybrid trial design to improve patient access. With topline results expected in the first half of 2026, the trial aims to explore how bezisterim may influence the progression of Parkinson's symptoms. The company's efforts were supported by prominent advocacy organizations in the Parkinson's community.

Read more →

About BioVie Inc.

Carson City, NV 13 employees bioviepharma.com
Headquarters680 W NYE LANE, CARSON CITY, NV, 89703
BIOPHARMAWATCH ELITE PLUS
Trade the next BIVI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime